165 related articles for article (PubMed ID: 20464152)
1. [Visceral leishmaniasis: retrospective study on factors associated with lethality].
Alvarenga DG; Escalda PM; Costa AS; Monreal MT
Rev Soc Bras Med Trop; 2010; 43(2):194-7. PubMed ID: 20464152
[TBL] [Abstract][Full Text] [Related]
2. [Mortality due to visceral leishmaniasis: clinical and laboratory characteristics].
Oliveira JM; Fernandes AC; Dorval ME; Alves TP; Fernandes TD; Oshiro ET; Oliveira AL
Rev Soc Bras Med Trop; 2010; 43(2):188-93. PubMed ID: 20464151
[TBL] [Abstract][Full Text] [Related]
3. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
4. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
5. Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil.
Brustoloni YM; Cunha RV; Cônsolo LZ; Oliveira AL; Dorval ME; Oshiro ET
Infection; 2010 Aug; 38(4):261-7. PubMed ID: 20508967
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the treatment of visceral leishmaniasis.
Davidson RN; Croft SL
Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of leishmaniasis in India.
Thakur CP
Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933
[No Abstract] [Full Text] [Related]
9. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
Barbosa JF; de Figueiredo SM; Lyon S; Caligiorne RB
Curr Clin Pharmacol; 2016; 11(4):265-269. PubMed ID: 27659611
[TBL] [Abstract][Full Text] [Related]
10. Glucantime-resistant visceral leishmaniasis in immunocompromised patients.
Verdejo J; Alvar J; Polo RM; González-Lahoz JM
Am J Med; 1988 Jul; 85(1):128. PubMed ID: 3389377
[No Abstract] [Full Text] [Related]
11. [Emergent outbreak of visceral leishmaniasis in Mato Grosso do Sul State].
Oliveira AL; Paniago AM; Dorval ME; Oshiro ET; Leal CR; Sanches M; Cunha RV; Bóia MN
Rev Soc Bras Med Trop; 2006; 39(5):446-50. PubMed ID: 17160321
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
[TBL] [Abstract][Full Text] [Related]
13. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
di Martino L; Mantovani MP; Gradoni L; Gramiccia M; Guandalini S
Trans R Soc Trop Med Hyg; 1990; 84(4):534-5. PubMed ID: 2091347
[No Abstract] [Full Text] [Related]
14. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol.
Hueso M; Bover J; Serón D; Gil-Vernet S; Rufí G; Alsina J; Grinyó JM
Nephrol Dial Transplant; 1999 Dec; 14(12):2941-3. PubMed ID: 10570102
[No Abstract] [Full Text] [Related]
15. [Treatment of visceral leishmaniasis in children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of infantile visceral leishmaniasis].
Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
18. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome.
Nonata R; Sampaio R; Marsden PD
Trans R Soc Trop Med Hyg; 1997; 91(1):77. PubMed ID: 9093636
[No Abstract] [Full Text] [Related]
19. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
20. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
Utili R; Rambaldi A; Tripodi MF; Andreana A
Infection; 1995; 23(3):182-3. PubMed ID: 7499009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
